Stage III Bladder Cancer AJCC v8: Clinical Trials

18 trials for Stage III Bladder Cancer AJCC v8, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 active not recruiting, 4 completed, 3 recruiting, 2 terminated. 13 Phase 2, 4 Phase 1, 1 Not applicable, 1 Phase 3, 1 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 213Active not recruiting 5, Completed 3, Recruiting 2, Terminated 2, Withdrawn 1
Phase 14Active not recruiting 2, Recruiting 1, Terminated 1
Not applicable1Active not recruiting 1
Phase 31Active not recruiting 1
Phase 41Recruiting 1

Follow Stage III Bladder Cancer AJCC v8: new trials by email Literature Review of Stage III Bladder Cancer AJCC v8 trials Research Report on Stage III Bladder Cancer AJCC v8

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial
Intensity-Modulated Radiation Therapy, Volume Modulated Arc Therapy, Radiosensitizing Agent - Muscle Invasive Bladder Carcinoma, Stage III Bladder Cancer AJCC v8
Phase 1 / Phase 2RecruitingUniversity of Washington122026-08-202026-08-25
Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial
Biospecimen Collection, Computed Tomography, Cystectomy - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma
Phase 4RecruitingMayo Clinic752025-01-082026-10-01
An Education and Navigation Support Tool to Improve Participation in Care Coordination Among Patients With Locally Advanced, Metastatic and Unresectable Bladder Cancer and Their Caregivers
Assessment of Distress, Consultation Visit, Nutritional Assessment - Locally Advanced Bladder Carcinoma, Metastatic Bladder Carcinoma
Not applicableActive not recruitingRoswell Park Cancer Institute122024-01-122026-11-05
Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial
Atezolizumab, Biospecimen Collection, Computed Tomography - Bladder Carcinoma, Bladder Urothelial Carcinoma
Phase 2WithdrawnNational Cancer Institute (NCI)2023-10-122025-10-21
Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology
Biospecimen Collection, Computed Tomography, Enfortumab Vedotin - Bladder Squamous Cell Carcinoma, Locally Advanced Bladder Carcinoma
Phase 2RecruitingEmory University252023-09-262026-07-29
Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study
Avelumab, Biospecimen Collection, Bone Scan - Advanced Bladder Urothelial Carcinoma, Advanced Renal Pelvis Urothelial Carcinoma
Phase 3Active not recruitingNational Cancer Institute (NCI)6542022-06-032026-11-12
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
Ipilimumab, Nivolumab, Tocilizumab - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Phase 2TerminatedM.D. Anderson Cancer Center352021-09-232026-11-17
ARID1A and/or KDM6A Mutation and CXCL13 Expression
Diagnostic Laboratory Biomarker Analysis, Nivolumab, Relatlimab - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma
Phase 2Active not recruitingM.D. Anderson Cancer Center62021-09-212026-10-06
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
Atezolizumab, Avelumab, Durvalumab - Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma
Phase 1 / Phase 2TerminatedM.D. Anderson Cancer Center192021-04-142026-04-30
A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial
Biopsy of Bladder, Biospecimen Collection, Cisplatin - Bladder Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8
Phase 2Active not recruitingNational Cancer Institute (NCI)112021-03-172026-11-17
Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes
Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Advanced Bladder Carcinoma, Advanced Genitourinary System Carcinoma
Phase 2Active not recruitingNational Cancer Institute (NCI)602020-11-032026-11-18
Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes
Patient Monitoring, Questionnaire Administration - Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8, Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8
CompletedCity of Hope Medical Center222020-08-112026-10-14
Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma
Phase 1 / Phase 2Active not recruitingNational Cancer Institute (NCI)302019-11-182026-11-18
Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma
Atezolizumab, Biopsy, Biospecimen Collection - Advanced Bladder Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma
Phase 2CompletedNational Cancer Institute (NCI)472019-06-052024-07-26
Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer
Avelumab, Cisplatin, Fluorouracil - Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Stage II Bladder Cancer AJCC v8
Phase 2CompletedMayo Clinic22018-09-192023-01-06
Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer
Atezolizumab, Biopsy Procedure, Biospecimen Collection - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma
Phase 2Active not recruitingNational Cancer Institute (NCI)722018-07-202026-11-18
Pembrolizumab in Treating Patients With Bladder Cancer Undergoing Radical Cystectomy
Pembrolizumab - Stage I Bladder Cancer AJCC v8, Stage II Bladder Cancer AJCC v8
Phase 2CompletedM.D. Anderson Cancer Center232018-01-112024-06-25
Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors
Biopsy Procedure, Biospecimen Collection, Cabozantinib S-malate - Bladder Small Cell Neuroendocrine Carcinoma, Bladder Squamous Cell Carcinoma
Phase 1Active not recruitingNational Cancer Institute (NCI)1522015-07-222026-11-18

Narrower conditions

Urinary Bladder Neoplasms (18)  ·  Ureteral Neoplasms (9)  ·  Urethral Neoplasms (7)  ·  Carcinoma, Transitional Cell (4)  ·  Carcinoma, Renal Cell (3)  ·  Lung Neoplasms (2)  ·  Urogenital Neoplasms (2)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Colorectal Neoplasms (1)  ·  Gastrointestinal Neoplasms (1)  ·  Melanoma (1)  ·  Neoplasms (1)  ·  Ovarian Neoplasms (1)  ·  Penile Neoplasms (1)  ·  Prostatic Neoplasms (1)

Broader conditions

Female Urogenital Diseases (18)  ·  Female Urogenital Diseases and Pregnancy Complications (18)  ·  Male Urogenital Diseases (18)  ·  Neoplasms by Site (18)  ·  Urinary Bladder Diseases (18)  ·  Urogenital Diseases (18)  ·  Urologic Diseases (18)  ·  Urologic Neoplasms (18)  ·  Neoplasms (17)  ·  Urogenital Neoplasms (16)  ·  Ureteral Diseases (9)  ·  Neoplasms by Histologic Type (8)  ·  Carcinoma (7)  ·  Neoplasms, Glandular and Epithelial (7)  ·  Urethral Diseases (7)

Interventions

Magnetic Resonance Spectroscopy (10)  ·  Specimen Handling (10)  ·  pembrolizumab (5)  ·  Biopsy (4)  ·  Nivolumab (4)  ·  atezolizumab (4)  ·  Cystoscopy (3)  ·  Disulfides (3)  ·  Immunoglobulin G (3)  ·  Radiation (3)  ·  Radiotherapy (3)  ·  avelumab (3)  ·  1,2-diaminocyclohexaneplatinum II citrate (2)  ·  CTLA-4 Antigen (2)  ·  Cisplatin (2)

Sponsors

National Cancer Institute (NCI) (8)  ·  M.D. Anderson Cancer Center (4)  ·  Mayo Clinic (2)  ·  City of Hope Medical Center (1)  ·  Emory University (1)  ·  Roswell Park Cancer Institute (1)  ·  University of Washington (1)

Countries

United States (17)  ·  Canada (2)

Top investigators

Andrea B Apolo (2)  ·  Anishka A D'Souza (1)  ·  Di Maria Jiang (1)  ·  Evan Y Yu (1)  ·  Jacob J. Orme, MD, PhD (1)  ·  Jacqueline Brown, MD (1)  ·  Laleh Melstrom (1)  ·  Maha H Hussain (1)  ·  Monika Joshi (1)  ·  Neema Navai (1)  ·  Paras H. Shah, MD (1)  ·  Parminder Singh (1)  ·  Rodabe Amaria, MD (1)  ·  Saby George, MD (1)  ·  Sangeeta Goswami (1)

Results publications

PMID 32915679, PMID 35031545, PMID 35537412, PMID 37328287, PMID 38954785, PMID 40580957

NIH funding

UM1CA186717 (2), ZIABC011078 (2), P30CA015704 (1), P30CA033572 (1), P30CA060553 (1), P30CA138292 (1), U01CA154967 (1), U10CA180820 (1), U10CA180821 (1), UM1CA186644 (1), UM1CA186712 (1), UM1CA186716 (1)